S ub-therapeutic use of antibiotic growth promoters (AGPs) has been practiced in the poultry industry since 1946 when Moore et al showed that their application resulted in weight gain in chickens. While their use has had a part to play in the 66% increase in broiler weight from 1960- 20101 , research has shown that the regular low levels of antibiotics used in animal production has – as Fleming predicted in his Nobel prize winning speech in 1945 – allowed resistant microbes to survive and evolve. Even as early as the 1950s, researchers2 were reporting resistance in birds to antibiotics regularly used to treat humans. Further evidence of drug-resistant bacteria3 drug residues in the body of the birds4 , an imbalance of normal micro flora5 and the transfer of antibiotic resistance genes from animal to human microbiota6 culminated in a total ban in AGP use in Sweden in 19867 . This ban spread across the EU in 2006 and Korea followed suit in 2011